Literature DB >> 1902245

Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.

S J Cryz1, E Fürer, J C Sadoff, T Fredeking, J U Que, A S Cross.   

Abstract

A hyperimmune globulin for intravenous use (H-IVIG) was prepared from the plasma of donors immunized with Pseudomonas aeruginosa and Klebsiella vaccines. H-IVIG preparations contained substantially higher IgG antibody levels to all nine P. aeruginosa vaccine antigens and to 22 of the 24 Klebsiella vaccine antigens than did commercial IVIG. The H-IVIG was more effective at promoting the opsonophagocytic killing of P. aeruginosa and Klebsiella vaccine serotype strains than normal IVIG. The H-IVIG neutralized greater than 20 times more toxin A than commercial IVIG. Only the H-IVIG offered significant protection against Klebsiella K2 sepsis. The H-IVIG provided significantly better protection against six of the eight P. aeruginosa vaccine serotypes than normal IVIG when compared in a murine burn wound sepsis model. The H-IVIG also protected mice against an Enterobacter aerogenes challenge, whereas normal IVIG was ineffective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902245     DOI: 10.1093/infdis/163.5.1055

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

3.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.

Authors:  Tanweer S Zaidi; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.

Authors:  Gregory P Priebe; Mary M Brinig; Kazue Hatano; Martha Grout; Fadie T Coleman; Gerald B Pier; Joanna B Goldberg
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.

Authors:  Gregory P Priebe; Gloria J Meluleni; Fadie T Coleman; Joanna B Goldberg; Gerald B Pier
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

8.  Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection.

Authors:  D E Schiff; C A Wass; S J Cryz; A S Cross; K S Kim
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

9.  Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors:  G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

10.  Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.

Authors:  K Hatano; G B Pier
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.